System-based approaches as prognostic tools for glioblastoma.
Apoptosis
Computational model
Glioblastoma
Molecular signatures
Network model
Numerical simulation
Precision oncology
Prognostic biomarker
Systems biology
Systems medicine
Journal
BMC cancer
ISSN: 1471-2407
Titre abrégé: BMC Cancer
Pays: England
ID NLM: 100967800
Informations de publication
Date de publication:
12 Nov 2019
12 Nov 2019
Historique:
received:
01
05
2019
accepted:
09
10
2019
entrez:
14
11
2019
pubmed:
14
11
2019
medline:
31
3
2020
Statut:
epublish
Résumé
The evasion of apoptosis is a hallmark of cancer. Understanding this process holistically and overcoming apoptosis resistance is a goal of many research teams in order to develop better treatment options for cancer patients. Efforts are also ongoing to personalize the treatment of patients. Strategies to confirm the therapeutic efficacy of current treatments or indeed to identify potential novel additional options would be extremely beneficial to both clinicians and patients. In the past few years, system medicine approaches have been developed that model the biochemical pathways of apoptosis. These systems tools incorporate and analyse the complex biological networks involved. For their successful integration into clinical practice, it is mandatory to integrate systems approaches with routine clinical and histopathological practice to deliver personalized care for patients. We review here the development of system medicine approaches that model apoptosis for the treatment of cancer with a specific emphasis on the aggressive brain cancer, glioblastoma. We discuss the current understanding in the field and present new approaches that highlight the potential of system medicine approaches to influence how glioblastoma is diagnosed and treated in the future.
Sections du résumé
BACKGROUND
BACKGROUND
The evasion of apoptosis is a hallmark of cancer. Understanding this process holistically and overcoming apoptosis resistance is a goal of many research teams in order to develop better treatment options for cancer patients. Efforts are also ongoing to personalize the treatment of patients. Strategies to confirm the therapeutic efficacy of current treatments or indeed to identify potential novel additional options would be extremely beneficial to both clinicians and patients. In the past few years, system medicine approaches have been developed that model the biochemical pathways of apoptosis. These systems tools incorporate and analyse the complex biological networks involved. For their successful integration into clinical practice, it is mandatory to integrate systems approaches with routine clinical and histopathological practice to deliver personalized care for patients.
RESULTS
RESULTS
We review here the development of system medicine approaches that model apoptosis for the treatment of cancer with a specific emphasis on the aggressive brain cancer, glioblastoma.
CONCLUSIONS
CONCLUSIONS
We discuss the current understanding in the field and present new approaches that highlight the potential of system medicine approaches to influence how glioblastoma is diagnosed and treated in the future.
Identifiants
pubmed: 31718568
doi: 10.1186/s12885-019-6280-2
pii: 10.1186/s12885-019-6280-2
pmc: PMC6852738
doi:
Substances chimiques
Biomarkers, Tumor
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1092Subventions
Organisme : Science Foundation Ireland
ID : 13/IA/1881
Pays : Ireland
Organisme : Science Foundation Ireland
ID : 14/IA/2582
Pays : Ireland
Organisme : Brain Tumor Ireland
ID : -
Organisme : European Union's Seventh Framework Programme for research, technological development, and demonstration
ID : 306021 (APO-DECIDE)
Organisme : International Training Network supported by the European Union's H2020 Programme for research
ID : 766069
Organisme : International Training Network supported by the European Union's H2020 Programme for research
ID : 766069
Références
J Neurooncol. 2017 Oct;135(1):183-192
pubmed: 28730289
JCO Clin Cancer Inform. 2017 Nov;1:1-7
pubmed: 30657404
Hum Pathol. 2015 Sep;46(9):1323-30
pubmed: 26190195
Br J Cancer. 2018 May;118(11):1492-1501
pubmed: 29765148
Int J Oncol. 2012 Jan;40(1):119-29
pubmed: 21879257
Sci Signal. 2011 Mar 22;4(165):ra16
pubmed: 21427409
Nat Methods. 2013 Nov;10(11):1108-15
pubmed: 24037242
Cancer. 2014 Dec 15;120(24):3972-80
pubmed: 25139333
Biophys J. 2007 Jun 15;92(12):4304-15
pubmed: 17400705
Oncotarget. 2016 Sep 20;7(38):61295-61311
pubmed: 27494880
J Neurooncol. 2016 Feb;126(3):567-75
pubmed: 26614518
Int J Clin Exp Med. 2015 Nov 15;8(11):20287-94
pubmed: 26884942
Nat Commun. 2019 Apr 16;10(1):1787
pubmed: 30992437
Nature. 2005 Oct 13;437(7061):1032-7
pubmed: 16136080
J Pathol. 2014 Jan;232(2):165-77
pubmed: 24114756
Cancer Res. 2013 Jan 15;73(2):519-28
pubmed: 23329644
Cell Death Differ. 2018 Nov;25(11):1952-1966
pubmed: 29500433
Proc Natl Acad Sci U S A. 2000 Jun 6;97(12):6242-4
pubmed: 10841526
Trends Biochem Sci. 2013 Dec;38(12):612-20
pubmed: 24239264
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
Endocrinology. 2009 Aug;150(8):3645-54
pubmed: 19406940
Gut. 2017 Dec;66(12):2141-2148
pubmed: 27663504
Mol Ther. 2012 Jan;20(1):1-2
pubmed: 22215048
Sci Rep. 2018 Apr 11;8(1):5805
pubmed: 29643433
J Biol Chem. 2012 Nov 30;287(49):41546-59
pubmed: 23038270
Biophys J. 2006 Mar 1;90(5):1546-59
pubmed: 16339882
Lancet Oncol. 2008 Jan;9(1):29-38
pubmed: 18082451
Sci Rep. 2018 Jul 25;8(1):11182
pubmed: 30046049
J Cell Biol. 2004 Sep 13;166(6):839-51
pubmed: 15364960
Cancer Res. 2013 May 15;73(10):2976-86
pubmed: 23400596
Cell Death Dis. 2018 Jan 25;9(2):121
pubmed: 29371590
Cancer Cell. 2010 Jan 19;17(1):98-110
pubmed: 20129251
Nat Rev Genet. 2015 Aug;16(8):441-58
pubmed: 26149713
Biotechnol J. 2012 Aug;7(8):946-57
pubmed: 22528809
Cancer Cell. 2010 May 18;17(5):510-22
pubmed: 20399149
J Biol Chem. 2007 May 4;282(18):13664-71
pubmed: 17347143
Proc Natl Acad Sci U S A. 2014 Aug 26;111(34):12550-5
pubmed: 25114226
Nat Commun. 2016 Aug 16;7:12474
pubmed: 27527408
PLoS One. 2015 Mar 04;10(3):e0118261
pubmed: 25739030
Biotechnol J. 2014 Sep;9(9):1115-28
pubmed: 25174503
Nature. 2006 Jan 19;439(7074):353-7
pubmed: 16273092
Int J Mol Sci. 2019 Jun 04;20(11):
pubmed: 31167470
Eur J Cancer. 2016 Nov;67:213-222
pubmed: 27689717
Nat Genet. 2016 Jul;48(7):768-76
pubmed: 27270107
Biosystems. 2007 Nov-Dec;90(3):591-601
pubmed: 17314003
Cell Rep. 2013 Jan 31;3(1):246-59
pubmed: 23318258
Cell Death Dis. 2018 Nov 1;9(11):1112
pubmed: 30385739
Oncotarget. 2015 Mar 20;6(8):5963-77
pubmed: 25849941
Cell Prolif. 1995 Jan;28(1):17-31
pubmed: 7833383
Proc Natl Acad Sci U S A. 2017 Jun 27;114(26):6812-6817
pubmed: 28607091
CPT Pharmacometrics Syst Pharmacol. 2018 Apr;7(4):219-227
pubmed: 29368434
Mol Cell. 2008 Apr 11;30(1):11-25
pubmed: 18406323
Sci Signal. 2015 Dec 22;8(408):ra130
pubmed: 26696630
Cancer Cell. 2017 Jul 10;32(1):42-56.e6
pubmed: 28697342
Cell. 2016 May 5;165(4):780-91
pubmed: 27153492
N Engl J Med. 2005 Mar 10;352(10):997-1003
pubmed: 15758010
Cancer Cell. 2015 Sep 14;28(3):318-28
pubmed: 26373279
Neurol Clin. 2018 Aug;36(3):421-437
pubmed: 30072063
Histopathology. 2019 Feb;74(3):372-376
pubmed: 30270453
Clin Transl Med. 2014 Mar 29;3(1):7
pubmed: 24679154
Proteomics Clin Appl. 2015 Apr;9(3-4):342-7
pubmed: 25594918
Biophys J. 2007 May 1;92(9):3332-4
pubmed: 17277182
Cell Death Dis. 2013 May 16;4:e629
pubmed: 23681224
Science. 2017 May 26;356(6340):
pubmed: 28495876
JCO Clin Cancer Inform. 2019 Apr;3:1-17
pubmed: 30995124
Neuro Oncol. 2016 Aug;18(8):1037-9
pubmed: 27236194
Br J Cancer. 2016 Jan 19;114(2):188-98
pubmed: 26657652
Sci Transl Med. 2019 Jan 2;11(473):
pubmed: 30602536
Cell Death Differ. 2009 Apr;16(4):613-23
pubmed: 19136937
Clin Cancer Res. 2018 Aug 1;24(15):3492-3499
pubmed: 29581134
Cancer Res. 2009 Dec 1;69(23):9065-72
pubmed: 19920198
EMBO J. 2006 Sep 20;25(18):4338-49
pubmed: 16932741
J Med Internet Res. 2017 Oct 16;19(10):e344
pubmed: 29038096
Proc Natl Acad Sci U S A. 2015 Jul 28;112(30):E4046-54
pubmed: 26170328
Lancet Oncol. 2009 May;10(5):459-66
pubmed: 19269895
Neuro Oncol. 2012 Sep;14 Suppl 4:iv100-8
pubmed: 23095825
Nucleic Acids Res. 2016 Jul 27;44(13):6019-35
pubmed: 27317695
Mol Syst Biol. 2015 May 07;11(5):803
pubmed: 25953765
Cell Death Dis. 2018 Mar 22;9(4):430
pubmed: 29567940
J Pers Med. 2017 Sep 01;7(3):
pubmed: 28862657
Sci Transl Med. 2015 Apr 15;7(283):283ra53
pubmed: 25877891
Oncotarget. 2016 Jun 7;7(23):34599-616
pubmed: 27129147
Proc Natl Acad Sci U S A. 2013 Mar 5;110(10):4009-14
pubmed: 23412337
Sci Signal. 2013 Aug 13;6(288):ra68
pubmed: 23943608
Proc Natl Acad Sci U S A. 2018 Mar 27;115(13):E2970-E2979
pubmed: 29531073
PLoS One. 2012;7(11):e49918
pubmed: 23209617
Science. 2004 Oct 22;306(5696):640-3
pubmed: 15499008
Cell. 2012 May 11;149(4):780-94
pubmed: 22579283
Cancer Res. 2009 Aug 15;69(16):6713-20
pubmed: 19638581
Mol Cell. 2012 Jul 27;47(2):306-19
pubmed: 22683265
Sci Transl Med. 2010 Nov 3;2(56):56rv4
pubmed: 21048218
Mol Syst Biol. 2011 Nov 22;7:553
pubmed: 22108795
Science. 2014 Jun 20;344(6190):1396-401
pubmed: 24925914
Cell Death Differ. 2010 Feb;17(2):278-90
pubmed: 19745831
Genome Med. 2016 Oct 26;8(1):113
pubmed: 27784327
J Biol Chem. 2004 Aug 27;279(35):36892-7
pubmed: 15208304
Lancet. 2005 Feb 19-25;365(9460):671-9
pubmed: 15721472
Nat Biotechnol. 2000 Jul;18(7):768-74
pubmed: 10888847
Cancer Cell. 2013 Sep 9;24(3):331-46
pubmed: 23993863
Cancer Cell. 2016 Apr 11;29(4):494-507
pubmed: 27070702
Sci Rep. 2019 Jul 11;9(1):10063
pubmed: 31296889
Curr Neurol Neurosci Rep. 2013 May;13(5):345
pubmed: 23532369
N Engl J Med. 2017 Nov 16;377(20):1954-1963
pubmed: 29141164
Clin Cancer Res. 2015 Nov 15;21(22):5030-6
pubmed: 26567362
Clin Cancer Res. 2016 Jul 15;22(14):3683-94
pubmed: 27001313
Cell. 2016 Jan 28;164(3):550-63
pubmed: 26824661
Mol Syst Biol. 2008;4:169
pubmed: 18277385
NPJ Precis Oncol. 2017 Jun 19;1(1):22
pubmed: 29872706
Nat Commun. 2017 Feb 15;8:
pubmed: 28198370
Immunity. 2018 Apr 17;48(4):812-830.e14
pubmed: 29628290
NPJ Breast Cancer. 2018 Sep 3;4:30
pubmed: 30182055
PLoS One. 2013;8(1):e51951
pubmed: 23372647
Exp Mol Med. 2018 Mar 2;50(3):e453
pubmed: 29497170
FEBS Lett. 2005 Mar 21;579(8):1891-5
pubmed: 15763569
Nat Rev Cancer. 2018 Jul;18(7):407-418
pubmed: 29692415
Cell Death Dis. 2016 Feb 04;7:e2087
pubmed: 26844701
J Intern Med. 2012 Feb;271(2):155-65
pubmed: 22142263
J Theor Biol. 2005 May 7;234(1):123-31
pubmed: 15721041
Cell. 2019 Aug 8;178(4):835-849.e21
pubmed: 31327527
Nat Immunol. 2017 Jun 20;18(7):725-732
pubmed: 28632713
BMJ Open. 2019 Feb 15;9(2):e025483
pubmed: 30772862
J Oncol Pract. 2016 Aug;12(8):737-44
pubmed: 27271506
Biophys J. 2009 Jul 22;97(2):415-34
pubmed: 19619456
Front Mol Biosci. 2018 Jul 26;5:70
pubmed: 30094238
Eur Respir Rev. 2018 Feb 7;27(147):
pubmed: 29436404
Mol Oncol. 2014 Jun;8(4):783-98
pubmed: 24725481
JCO Clin Cancer Inform. 2019 Feb;3:1-9
pubmed: 30730766
Gut. 2012 May;61(5):725-33
pubmed: 22082587
Proc Natl Acad Sci U S A. 2019 Mar 26;116(13):6435-6440
pubmed: 30846550
Pathol Oncol Res. 2020 Oct;26(4):2035-2047
pubmed: 31376079
Nat Genet. 2018 May;50(5):708-717
pubmed: 29686388
Biochim Biophys Acta. 2011 Apr;1813(4):608-15
pubmed: 20950651
Biomed Res Int. 2017;2017:7403747
pubmed: 29259986
Acta Neuropathol. 2018 May;135(5):649-670
pubmed: 29616301
Biochim Biophys Acta. 2009 Apr;1795(2):117-29
pubmed: 19167459
Genes Dev. 2012 Apr 15;26(8):756-84
pubmed: 22508724
Cell. 2000 Jan 7;100(1):57-70
pubmed: 10647931
Nat Commun. 2014 May 29;5:3887
pubmed: 24871328
Nature. 2008 Oct 23;455(7216):1061-8
pubmed: 18772890
PLoS Comput Biol. 2014 Oct 23;10(10):e1003893
pubmed: 25340343
Neuro Oncol. 2018 Jun 18;20(7):873-884
pubmed: 29432615
Proc Natl Acad Sci U S A. 2013 Jul 16;110(29):11982-7
pubmed: 23818604
Biomed Res Int. 2017;2017:8013575
pubmed: 28316990
Nat Rev Cancer. 2017 Apr;17(4):254-268
pubmed: 28104906
N Engl J Med. 2011 Feb 17;364(7):627-37
pubmed: 21175304
PLoS Genet. 2013 Apr;9(4):e1003464
pubmed: 23637631
BMC Syst Biol. 2008 Aug 12;2:74
pubmed: 18700030
Nat Genet. 2017 Apr;49(4):594-599
pubmed: 28263318
J Neurooncol. 2017 Jan;131(1):11-20
pubmed: 27633774
EGEMS (Wash DC). 2015 Mar 04;3(1):1127
pubmed: 25992389
Clin Cancer Res. 2017 Mar 1;23(5):1200-1212
pubmed: 27649552
Front Cell Dev Biol. 2019 Feb 18;7:16
pubmed: 30834247
Clin Cancer Res. 2018 Sep 15;24(18):4429-4436
pubmed: 29789422
Mol Cell Oncol. 2014 Dec 23;1(3):e964037
pubmed: 27308353
BMC Syst Biol. 2018 Apr 25;12(1):57
pubmed: 29699591
Cell Death Dis. 2016 Jan 14;7:e2052
pubmed: 26775704
N Engl J Med. 2002 Dec 19;347(25):1999-2009
pubmed: 12490681
PLoS Comput Biol. 2012;8(4):e1002482
pubmed: 22570596
Cell. 2015 Nov 19;163(5):1059-1063
pubmed: 26590416
PLoS Comput Biol. 2018 Jan 2;14(1):e1005924
pubmed: 29293494
Nat Commun. 2018 Jan 26;9(1):389
pubmed: 29374163
BMC Med. 2019 Jan 16;17(1):11
pubmed: 30646913
J Clin Oncol. 2008 Sep 1;26(25):4189-99
pubmed: 18757334
Cell Death Dis. 2018 Jan 19;9(2):42
pubmed: 29352235
Cancer Lett. 2016 Sep 28;380(1):31-8
pubmed: 27267809
J Neurooncol. 2018 Jan;136(1):1-11
pubmed: 29081039
BMC Syst Biol. 2010 Feb 04;4:9
pubmed: 20132548
Mol Cancer Ther. 2003 Jun;2(6):573-80
pubmed: 12813137
Front Physiol. 2019 Jan 24;9:1965
pubmed: 30733688
JCO Clin Cancer Inform. 2018 Dec;2:1-12
pubmed: 30652561
Cell. 2018 Apr 5;173(2):338-354.e15
pubmed: 29625051
Front Oncol. 2018 Jun 21;8:228
pubmed: 29977864
PLoS Comput Biol. 2006 Sep 15;2(9):e120
pubmed: 16978046
N Engl J Med. 2005 Mar 10;352(10):987-96
pubmed: 15758009
Cell Death Dis. 2014 May 29;5:e1258
pubmed: 24874730
JAMA Oncol. 2016 Nov 01;2(11):1460-1469
pubmed: 27310651
NPJ Precis Oncol. 2017 Sep 18;1(1):33
pubmed: 29872714
Sci Signal. 2014 Mar 11;7(316):ra23
pubmed: 24619646